Biosimilars approved in Chile

Biosimilars/General | Posted 19/11/2021 post-comment0 Post your comment

In Chile, the regulatory body responsible for the approval of biological medicines is the National Drug Agency (Agencia Nacional de Medicamentos, ANAMED), which is part of the Institute of Public Health of Chile (ISP), under the Ministry of Health.

ANAMED V21K19LT

ANAMED’s main functions include controlling authorized pharmaceutical, cosmetic and health products, whether manufactured locally or imported to be sold in the country, ensuring their quality, safety and efficacy; issue the necessary authorizations and provide registrations of pharmaceutical products and cosmetic; and control the distribution and dispensing of narcotic drugs and psychotropic substances, as well as their precursors, updating the databases of their use to comply with international agreements on the control of these substances.

On 21 August 2014, ISP approved Technical Standard No. 170 for the Health Registration of Biotechnological Products derived from recombinant DNA techniques, a regulation that is based on international criteria and that follows the World Health Organization’s (WHO) recommendations for the presentation and evaluation of the specific antecedents that they must be entered together with the applications for health registration of reference biotherapeutic products (RBP) and similar biotherapeutic products (SBP).

ISP defines biosimilars as medicines that have been shown to have quality, safety, efficacy and immunogenicity attributes similar to a reference biotherapeutic product.

To date, ANAMED has approved 14 biosimilars [1] within the product classes of: 1) monoclonal antibodies; 2) granulocyte colony-stimulating factor; 3) insulin; 4) tumour necrosis factor (TNF)-inhibitor for use in Chile, see Table 1.

Table 1: Biosimilars approved by ANAMED
Product name Active substance Therapeutic area Manufacturer/
Company name
Alpha 2a recombinant human interferon alfa-2a Carcinoid tumour
Hepatitis B and C
Kaposi sarcoma
Follicular lymphoma
Malignant melanoma
Multiple myeloma
Blau Farmacêutica SA
Basaglar insulin glargine Diabetes Eli Lilly
Biofigran recombinant human interferon alfa-2b Carcinoid tumour
Hepatitis B and C
Kaposi sarcoma
Follicular lymphoma
Malignant melanoma
Multiple myeloma
BioSidus SA
Blautrim filgrastim Neutropenia Blau Farmacêutica SA
Filgen filgrastim Neutropenia Bioproforma Bago SA
Foltran filgrastim Neutropenia Lab Clausen
Heberon Alfa R interferón humano recombinante alfa-2b Carcinoid tumour
Hepatitis B and C
Kaposi sarcoma
Follicular lymphoma
Malignant melanoma
Multiple myeloma
Herber Biotec
INF recombinant human interferon alfa-2b Carcinoid tumour
Hepatitis B and C
Kaposi sarcoma
Follicular lymphoma
Malignant melanoma
Multiple myeloma
Laboratorios Bioprofarma SA
Interferon alfa 2b hm interferón humano recombinante alfa-2a Carcinoid tumour
Hepatitis B and C
Kaposi sarcoma
Follicular lymphoma
Malignant melanoma
Multiple myeloma
Dong-A ST Co, Ltd
IorâLeukoCIM filgrastim Neutropenia Centro de Inmunología Molecular (CIM)
Lioplin filgrastim Neutropenia Dong-A ST Co, Ltd
Neutrofil filgrastim Neutropenia Lab Pablo Cassara SRL
Remsina (CT-P13) infliximab Crohn's disease
Psoriasis
Psoriasic arthritis
Rheumatoid arthritis
Rheumatoid spondylitis
Ulcerative colitis
Celltrion
Zarzio filgrastim Neutropenia Sandoz
*Data updated on 19 November 2021.
Source: ANAMED [1].

 

Two biomimics are also authorized in Chile: -
1. Histocan, a biomimic of interferon alfa-2a for the treatment of hepatitis B and C, kaposi sarcoma, multiple myeloma, follicular lymphoma, carcinoid tumour and malignant melanoma
2. Reditux, a biomimic of rituximab, for the treatment of leukaemia, rheumatoid arthritis and lymphomas.

Interferon alfa-2a belongs to the non-licensed therapeutic class of interferon in Europe [2].

Biomimics are intended copies, unregulated biologicals, biocopies, which cannot be considered biosimilars unless they have been reviewed and approved by the appropriate regulatory agencies in accordance with the international guidelines provided by WHO for the approval of biosimilars [3].

Editor’s comment
European Medicines Agency regulatory requirements ensure the same high standards of quality, safety, and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product but they are not universally accepted by regulatory bodies outside of the European Union (EU). It should be noted that ‘biosimilars’ approved in Chile might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Related articles
The biosimilars market in Latin America: a summary

Similar biotherapeutic products approved and marketed in Latin America

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Regulación del registro de medicamentos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Regulación del registro de medicamentos biológicos en América Latina

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. Ortiz-Prado E, Ponce-Zea J, Vasconez JE, et al. Current trends for biosimilars in the Latin American market. Generics Biosimilars Initiative Journal. (GaBI Journal). 2020;9(2):64-74. doi:10.5639/gabij.2020.0902.011
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 19]. Available from: www.gabionline.net//Biosimilars/General/Biosimilars-approved-in-Europe
3. GaBI Online - Generics and Biosimilars Initiative. Glosario de términos principales [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 19]. Available from: www.gabionline.net/es/biosimilares/general/glosario-de-terminos-principales

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: ANAMED, ISP

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010